The Food and Drug Administration has approved the use of Lucilia cuprina, or Australian sheep blowfly, alongside its more common cousin Lucilia sericata for maggot wound therapy. This makes Cuprina Holdings the only company to hold FDA clearance for both species, positioning them as leaders in this niche market.

Cuprina CEO David Quek expressed confidence: 'We now hold an unassailable position in MDT, which is a testament to our commitment and innovation.' The company believes that while both maggots serve similar purposes, they cater to different markets with varying levels of familiarity. L. sericata is more recognized in Western countries, whereas L. cuprina may be more familiar in Australia, Africa, Asia, and parts of the Americas.

Dr Ronald Sherman, Cuprina’s Medical and Scientific Director, sees this as a significant step: 'The addition of another FDA-cleared species will enhance the flexibility of MDT treatment options for clinicians and their patients.' He added that maggot therapy has proven its worth in modern medicine and is set to continue expanding its reach.

The approval process highlights the growing acceptance of unconventional medical treatments, balancing traditional practices with stringent regulatory standards. As more companies explore these methods, it’s clear that even nature’s most unorthodox solutions are being brought into the fold.